Advances in grain research illuminate potential for precision nutrition in clinical settings

Treatment with the antibody drug-conjugate ifinatamab deruxtecan (I-DXd) showed promising activity in pretreated patients with extensive-stage small cell lung cancer (SCLC), particularly those treated at

Ar­cutis is jump­ing in­to the pso­ri­a­sis TV ad mar­ket with its first-ever com­mer­cial for Zorvye, its non-steroid cream ap­proved in Ju­ly 2022. The mes­sage be­hind